The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions.
about
Novel monoamine oxidase A knock out mice with human-like spontaneous mutationMonoamine oxidase: from genes to behaviorMulti-Target Directed Donepezil-Like Ligands for Alzheimer's DiseaseRasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase BThe central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson's disease.In vivo quantification of monoamine oxidase A in baboon brain: a PET study using [(11)C]befloxatone and the multi-injection approachMonoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: evidence for selective and reversible inhibition of monoamine oxidase type A in vivo but not in vitro.Effects of amphetamine on subcellular distribution of dopamine and DOPAC.Methylmercury impairs canonical dopamine metabolism in rat undifferentiated pheochromocytoma (PC12) cells by indirect inhibition of aldehyde dehydrogenase.Lower Monoamine Oxidase-A Total Distribution Volume in Impulsive and Violent Male Offenders with Antisocial Personality Disorder and High Psychopathic Traits: An [(11)C] Harmine Positron Emission Tomography StudyInhibition of Excessive Monoamine Oxidase A/B Activity Protects Against Stress-induced Neuronal Death in Huntington Disease.Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.Considering the causes of RLS.Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation.Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline.Presynaptic dopaminergic function: implications for understanding treatment response in psychosis.Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond.Rasagiline in treatment of Parkinson's disease.Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline.Synthesis of some novel 2-substituted benzothiazole derivatives containing benzylamine moiety as monoamine oxidase inhibitory agents.Synthesis and Screening of Human Monoamine Oxidase-A Inhibitor Effect of New 2-Pyrazoline and Hydrazone Derivatives.Selective monoamine oxidase subtype inhibition and striatal extracellular dopamine in the guinea-pig.Guinea pig striatum as a model of human dopamine deamination: the role of monoamine oxidase isozyme ratio, localization, and affinity for substrate in synaptic dopamine metabolism.Adaptive changes in postsynaptic dopamine receptors despite unaltered dopamine dynamics in mice lacking monoamine oxidase B.Homeostatic mechanisms in dopamine synthesis and release: a mathematical model.Monoamine Oxidase Inhibitory Activity of Novel Pyrazoline Analogues: Curcumin Based Design and Synthesis.Monoamine oxidase-A selective inhibition in human hypothalamus and liver in-vitro by amiflamine and its metabolites.Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor.The inhibition of monoamine oxidase by tricyclic antidepressants: the influence of the nature of the substrate and the source of the enzyme.Regulatory Pathways of Monoamine Oxidase A during Social Stress.1-[2-(4-Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease.Apomorphine protects against MPTP-induced neurotoxicity in mice.Characterization of Dopaminergic System in the Striatum of Young Adult Park2-/- Knockout Rats.Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.MAOA:FAD oxidatively deaminates of 5HToxidation of dopamine to 3;4dihydroxyphenylacetic acid (DOPAC)Pharmacokinetics of Rasagiline in Healthy Adult Chinese Volunteers with Various Genotypes: A Single-Center, Open-Label, Multiple-Dose Study.
P2860
Q24606127-99D586A1-4037-4D13-A4C6-AB8176A51471Q24614980-CEBEC47A-7C29-45D3-BC68-B648ACB900E6Q26744105-E2E9A439-95F6-4D37-A5FD-ADB40AEEA9ACQ28346410-F98F1A18-FF49-484E-B85C-1F3641A6FA0BQ31789217-1F522634-A255-4039-9CA6-1632E5FB062DQ33950517-CD1720CD-DA63-4393-BA14-3ED8D9EB41EAQ34170958-64EDD7A5-7D8A-4136-BF4D-7310A2D164A8Q34175385-6CCEC0BB-A61C-4D98-B638-B26A9A3DF32CQ34252846-A96EDE49-A64F-4FD8-9019-6F80DC2E3102Q35214603-B0B3EB3D-EC71-43D8-8AC9-C1619D8411F4Q36059906-8B604D39-BADD-4E83-8059-6D086FEEFCAFQ36100251-D00CF052-47E3-4E60-82CE-32A73F10BE8AQ36307876-7D8F3D71-C975-4E95-ADF2-1BFB86AF9E2BQ36575976-3EFB6473-BCD6-462B-8484-ED0C805CF17BQ37630366-AD06A885-049F-42D8-AE17-29148A0D6655Q37939755-A55470C3-5602-49A0-89F2-7FCBFEACE875Q38219577-AF5A5C30-E25B-4D5F-A89D-7CF1B85BDAC1Q38447289-7F995D94-35EA-4F5F-B917-0E6936EF496DQ39315311-0373970E-A8CE-48C7-AE8A-72D89DA1D9B9Q39694072-5F1BBB7D-8585-4066-9E35-49E586DCB42CQ39877764-9FB2CA43-2A00-4424-8A75-7BF1515104F7Q40621702-1018BA7F-E658-4AD3-B7F5-E1BDB6BF778DQ42192457-9D2F1E8C-DA09-49A5-8882-89A1D934D74CQ42226041-07593CF1-2D93-4436-8BFC-EDB4DE905FCEQ42475587-3B503210-A69E-48CB-A2E5-5EE2F902E4B7Q42574775-5AA2DC98-0B78-4CC6-B36D-30E606CAF710Q43083902-1D01DBBF-2AB8-4495-BBF0-1F35780549FAQ43734263-F80013CB-373F-46EF-B8B0-325441D243F5Q45208978-1F789200-8BC8-4AF4-AEAA-C4BD9EE208E7Q46756525-C8B67D46-44FD-4438-BDC6-DFE6593E7705Q47171927-3ABF48CE-E176-4F05-824D-8588E3F963D9Q48108548-4569EC91-55A8-4C70-99D7-548E1C934618Q48144127-FB427F6F-5FE9-4A73-8B3B-D985040BA4EDQ48171776-695C7FF0-81B5-425B-8FEC-A568061457CCQ48352927-793449A6-A00C-42E5-ABA5-C66E15B36CD4Q50295319-A469DB6E-8DC9-4DC8-A59A-8D5B8EFB2876Q50297052-E696F9AB-3813-4800-A7E5-F50E40E62BAAQ51287697-6FFF0140-317E-4A19-B53F-F1CAA0F5E809
P2860
The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions.
description
1983 nî lūn-bûn
@nan
1983 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1983 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1983年の論文
@ja
1983年論文
@yue
1983年論文
@zh-hant
1983年論文
@zh-hk
1983年論文
@zh-mo
1983年論文
@zh-tw
1983年论文
@wuu
name
The deamination of dopamine by ...... forms in seven brain regions.
@ast
The deamination of dopamine by ...... forms in seven brain regions.
@en
The deamination of dopamine by ...... forms in seven brain regions.
@nl
type
label
The deamination of dopamine by ...... forms in seven brain regions.
@ast
The deamination of dopamine by ...... forms in seven brain regions.
@en
The deamination of dopamine by ...... forms in seven brain regions.
@nl
altLabel
The deamination of dopamine by ...... e forms in seven brain regions
@en
prefLabel
The deamination of dopamine by ...... forms in seven brain regions.
@ast
The deamination of dopamine by ...... forms in seven brain regions.
@en
The deamination of dopamine by ...... forms in seven brain regions.
@nl
P2093
P3181
P356
P1476
The deamination of dopamine by ...... forms in seven brain regions.
@en
P2093
A M O'Carroll
C J Fowler
J P Phillips
K F Tipton
P2888
P304
P3181
P356
10.1007/BF00500765
P407
P577
1983-04-01T00:00:00Z
P6179
1021867102